Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles

ABSTRACT In this study, we investigated the potential of intradermal delivery of nanoparticulate vaccines to modulate the immune response of protein antigen using hollow microneedles. Four types of nanoparticles covering a broad range of physiochemical parameters, namely poly (lactic‐co‐glycolic) (PLGA) nanoparticles, liposomes, mesoporous silica nanoparticles (MSNs) and gelatin nanoparticles (GNPs) were compared. The developed nanoparticles were loaded with a model antigen (ovalbumin (OVA)) with and without an adjuvant (poly(I:C)), followed by the characterization of size, zeta potential, morphology, and loading and release of antigen and adjuvant. An in‐house developed hollow‐microneedle applicator was used to inject nanoparticle suspensions precisely into murine skin at a depth of about 120 &mgr;m. OVA/poly(I:C)‐loaded nanoparticles and OVA/poly(I:C) solution elicited similarly strong total IgG and IgG1 responses. However, the co‐encapsulation of OVA and poly(I:C) in nanoparticles significantly increased the IgG2a response compared to OVA/poly(I:C) solution. PLGA nanoparticles and liposomes induced stronger IgG2a responses than MSNs and GNPs, correlating with sustained release of the antigen and adjuvant and a smaller nanoparticle size. When examining cellular responses, the highest CD8+ and CD4+ T cell responses were induced by OVA/poly(I:C)‐loaded liposomes. In conclusion, the applicator controlled hollow microneedle delivery is an excellent method for intradermal injection of nanoparticle vaccines, allowing selection of optimal nanoparticle formulations for humoral and cellular immune responses. Graphical abstract Figure. No caption available.

[1]  Wim E. Hennink,et al.  Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles , 2000, Pharmaceutical Research.

[2]  D. Irvine,et al.  Particulate vaccines: on the quest for optimal delivery and immune response. , 2011, Drug discovery today.

[3]  S. Vyas,et al.  Nanoparticle-based immunopotentiation via tetanus toxoid-loaded gelatin and aminated gelatin nanoparticles , 2011, Drug delivery.

[4]  H. Mitsui,et al.  Langerhans cells exhibit low responsiveness to double-stranded RNA. , 2004, Biochemical and biophysical research communications.

[5]  B. Sl,et al.  PLGA particulate delivery systems for subunit vaccines : Linking particle properties to immunogenicity , 2016 .

[6]  P. Andersen,et al.  Cationic liposomes as vaccine adjuvants , 2007, Expert review of vaccines.

[7]  S. Nakagawa,et al.  Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. , 2011, Vaccine.

[8]  W. Jiskoot,et al.  Cationic Liposomes Loaded with a Synthetic Long Peptide and Poly(I:C): a Defined Adjuvanted Vaccine for Induction of Antigen-Specific T Cell Cytotoxicity , 2014, The AAPS Journal.

[9]  J. Harty,et al.  Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. , 2007, Immunity.

[10]  John Samuel,et al.  Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[11]  J. Bouwstra,et al.  Improved piercing of microneedle arrays in dermatomed human skin by an impact insertion method. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Zhengrong Cui,et al.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses , 2010, Expert review of vaccines.

[13]  Koen van der Maaden,et al.  Mesoporous Silica Nanoparticle-Coated Microneedle Arrays for Intradermal Antigen Delivery , 2017, Pharmaceutical Research.

[14]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[15]  Thomas Hankemeier,et al.  Novel Hollow Microneedle Technology for Depth-Controlled Microinjection-Mediated Dermal Vaccination: A Study with Polio Vaccine in Rats , 2014, Pharmaceutical Research.

[16]  W. Jiskoot,et al.  Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[17]  J. Jansen,et al.  Oppositely Charged Gelatin Nanospheres as Building Blocks for Injectable and Biodegradable Gels , 2011, Advanced materials.

[18]  W. Jiskoot,et al.  Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? , 2010, Molecular pharmaceutics.

[19]  H. Merkle,et al.  Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. , 2013, Advanced drug delivery reviews.

[20]  Koen van der Maaden,et al.  Microneedle technologies for (trans)dermal drug and vaccine delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Ahmed O Elzoghby,et al.  Protein-based nanocarriers as promising drug and gene delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[22]  D. Schrijvers,et al.  Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. , 2015, Pharmacology & therapeutics.

[23]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[24]  Leisha M. Armijo,et al.  Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[25]  A. Bajpai,et al.  Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate , 2006, Journal of materials science. Materials in medicine.

[26]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[27]  D. Duffy,et al.  Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. , 2011, Vaccine.

[28]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[29]  J. Moon,et al.  Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy , 2015, Vaccines.

[30]  Ahmed O Elzoghby,et al.  Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Joke Bouwstra,et al.  Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles , 2016, Pharmaceutical Research.

[32]  W. Jiskoot,et al.  Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Yvonne Perrie,et al.  Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[34]  W. Jiskoot,et al.  Adjuvant effect of cationic liposomes and CpG depends on administration route. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[35]  W. Jiskoot,et al.  Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation. , 2015, Vaccine.

[36]  E. Unanue,et al.  Phospholipids enhance the binding of peptides to class II major histocompatibility molecules. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. H. van der Burg,et al.  CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. , 2015, Biomaterials.

[38]  Koichiro Nakamura,et al.  Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. , 2004, The Journal of investigative dermatology.

[39]  Koen van der Maaden,et al.  Repeated fractional intradermal dosing of an inactivated polio vaccine by a single hollow microneedle leads to superior immune responses. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[40]  B. Verrier,et al.  Critical Role for Skin-Derived Migratory DCs and Langerhans Cells in TFH and GC Responses after Intradermal Immunization. , 2017, The Journal of investigative dermatology.

[41]  J. Oostendorp,et al.  Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  C. Russell Middaugh,et al.  Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.

[43]  N. Mitter,et al.  Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. , 2013, Small.

[44]  A. Alshamsan,et al.  Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. , 2008, Vaccine.

[45]  W. Jiskoot,et al.  Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. , 2011, Vaccine.

[46]  Chun-Xia Zhao,et al.  Nanoparticle vaccines. , 2014, Vaccine.

[47]  Ryan F. Donnelly,et al.  Skin Dendritic Cell Targeting via Microneedle Arrays Laden with Antigen-Encapsulated Poly-d,l-lactide-co-Glycolide Nanoparticles Induces Efficient Antitumor and Antiviral Immune Responses , 2013, ACS nano.

[48]  D. Busch,et al.  TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. , 2008, Vaccine.

[49]  Mitsuru Akashi,et al.  Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine , 2011 .

[50]  A. Boyle,et al.  Mesoporous Silica Nanoparticles with Large Pores for the Encapsulation and Release of Proteins. , 2016, ACS applied materials & interfaces.

[51]  Robert Langer,et al.  Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres , 2004, Pharmaceutical Research.

[52]  R. Löbenberg,et al.  Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[53]  N. Mitter,et al.  Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. , 2013, Nanoscale.